These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 2159176)

  • 1. One way protection between equid herpesvirus 1 and 4 in vivo.
    Edington N; Bridges CG
    Res Vet Sci; 1990 Mar; 48(2):235-9. PubMed ID: 2159176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies.
    Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine responses to EHV-1 infection in immune and non-immune ponies.
    Coombs DK; Patton T; Kohler AK; Soboll G; Breathnach C; Townsend HG; Lunn DP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):109-16. PubMed ID: 16473413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.
    Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus).
    Fitzpatrick DR; Studdert MJ
    Am J Vet Res; 1984 Oct; 45(10):1947-52. PubMed ID: 6208822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical signs and humoral immune response in horses following equine herpesvirus type-1 infection and their susceptibility to equine herpesvirus type-4 challenge.
    Stokes A; Corteyn AH; Murray PK
    Res Vet Sci; 1991 Sep; 51(2):141-8. PubMed ID: 1664967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
    Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC
    Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic restriction of cytolysis during equid herpesvirus 1 subtype 2 infection.
    Bridges CG; Edington N
    Clin Exp Immunol; 1987 Nov; 70(2):276-82. PubMed ID: 2827921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges.
    Patel JR; Földi J; Bateman H; Williams J; Didlick S; Stark R
    Vet Microbiol; 2003 Mar; 92(1-2):1-17. PubMed ID: 12488066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate immunity during Equid herpesvirus 1 (EHV-1) infection.
    Bridges CG; Edington N
    Clin Exp Immunol; 1986 Jul; 65(1):172-81. PubMed ID: 2431815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte responses to virus and mitogen in ponies during experimental infection with equine herpesvirus 1.
    Dutta SK; Myrup A; Bumgardner MK
    Am J Vet Res; 1980 Dec; 41(12):2066-8. PubMed ID: 6259978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 2 virus.
    Mumford JA; Bates J
    Vet Rec; 1984 Apr; 114(15):375-81. PubMed ID: 6328729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inoculation of mares and very young foals with EHV-1 glycoproteins D and B reduces virus shedding following respiratory challenge with EHV-1.
    Foote CE; Raidal SL; Pecenpetelovska G; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2006 May; 111(1-2):97-108. PubMed ID: 16504306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro cytotoxicity of serum and peripheral blood leukocytes for equine herpesvirus type 1-infected target cells.
    Wilks CR
    Am J Vet Res; 1977 Jan; 38(1):117-21. PubMed ID: 189645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).
    Goodman LB; Wagner B; Flaminio MJ; Sussman KH; Metzger SM; Holland R; Osterrieder N
    Vaccine; 2006 Apr; 24(17):3636-45. PubMed ID: 16513225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection.
    Paillot R; Ellis SA; Daly JM; Audonnet JC; Minke JM; Davis-Poynter N; Hannant D; Kydd JH
    Vaccine; 2006 Mar; 24(10):1490-500. PubMed ID: 16269205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV).
    Rosas CT; Tischer BK; Perkins GA; Wagner B; Goodman LB; Osterrieder N
    Virus Res; 2007 Apr; 125(1):69-78. PubMed ID: 17241683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the serological response of specific pathogen-free (EHV-free) foals to EHV-1 by previous infection with EHV-4 or a TK-deletion mutant of EHV-1.
    Tewari D; Gibson JS; Slater JD; O'Neill T; Hannant D; Allen GP; Field HJ
    Arch Virol; 1993; 132(1-2):101-20. PubMed ID: 8394686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus.
    Holmes MA; Townsend HG; Kohler AK; Hussey S; Breathnach C; Barnett C; Holland R; Lunn DP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):67-80. PubMed ID: 16476488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
    Van de Walle GR; May MA; Peters ST; Metzger SM; Rosas CT; Osterrieder N
    Vaccine; 2010 Jan; 28(4):1048-55. PubMed ID: 19897066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.